TrialCancer2015

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.

Rana R McKay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.